Recently, the latest research by the dean of the University of Michigan School of Public Health and his team concluded that there is sufficient evidence to support e-cigarettes as the primary aid for adults to quit smoking, and suggested that the governments of the United States, Australia and Canada, as well as professional medical teams, should Consider more about the potential of e-cigarettes in smoking cessation and reduce misperceptions about them.

In addition, many universities in Switzerland have used magnetic resonance testing to find that nicotine e-cigarettes are less harmful to the lungs than cigarettes.

Currently, the public controversy over nicotine e-cigarettes is mainly about their risks to teenagers and their potential for adults to quit smoking. Professor Kenneth Warner, dean of the School of Public Health at the University of Michigan, believes that the goals of promoting e-cigarettes as a harm reduction tool and reducing youth use of e-cigarettes do not conflict, and the focus lies on effective publicity by the government and the media.

Professor Kenneth Warner also co-authored the article "Nicotine e-cigarettes as a tool for smoking cessation" with colleagues from King's College London, Harvard University and other universities, which was published in the medical journal of Nature.

The paper states that there is sufficient evidence that e-cigarettes can be used as a primary aid in smoking cessation in adults, however, very little public and healthcare professionals are aware of its potential value in harm reduction. Using a global perspective, Professor Warner's team analyzed numerous countries that use e-cigarettes as a smoking cessation option and smoke-free countries. They found that in the United Kingdom and New Zealand, e-cigarettes have received high levels of support and promotion as a smoking cessation option, while in the United States, Canada and Australia Although these countries recognize the potential advantages of e-cigarettes, they cannot get effective recommendations from governments and medical institutions.

They also cited the FDA (US Food and Drug Administration) designation of some e-cigarette brands as "suitable to protect public health" as a reason for listing standards, saying that this behavior "indirectly implies that FDA believes that e-cigarettes can help some people quit smoking, otherwise they would won't do that."

Another study initiated by the University of Bern, University of Zurich, and University of Basel in Switzerland concluded that nicotine e-cigarettes can effectively promote lung perfusion and blood flow.

The researchers used magnetic resonance imaging to monitor lung function in 44 healthy participants. It was found that compared with normal conditions, tobacco users had significantly reduced lung perfusion/blood flow after smoking, while e-cigarette users had enhanced lung perfusion/blood flow after using nicotine e-cigarettes. The researchers believe this means that nicotine e-cigarettes do not inhibit lung function like traditional cigarette smoke, and also prove that nicotine e-cigarettes have less impact on lung damage.

The two studies by Professor Warner and Swiss universities both recognized the great potential of e-cigarettes as a harm reduction tool. As Professor Warner stated in the paper, e-cigarettes are not a panacea to end the harm of tobacco, but they can do something for this noble public health goal. contribute.